Admedus (ASX: AHZ) today announced the transaction to acquire an established manufacturing site from Genzyme Australia to facilitate scaled-up production of its lead regenerative tissue product CardioCel® has now been completed. The transaction was completed on the 31st of December, 2013 in accordance to the share purchase agreement.
- Forums
- ASX - Day Trading
- day trading jan 3 - all day
day trading jan 3 - all day, page-6
-
- There are more pages in this discussion • 305 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online